Company Overview and News

17
Subsidiary of Coeur Mining, Inc. signs Definitive Agreement with Evrim Resources to option Sarape gold-silver project

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Evrim Resources Corp. (TSX-V:EVM) (“Evrim” or the “Company”) is pleased to announce that further to its news release of February 20, 2018, the Company has signed a Definitive Agreement (the “Agreement”) with a subsidiary of Coeur Mining, Inc. (“Coeur”) in respect of the Sarape epithermal gold-silver project in Sonora, Mexico. Coeur will have the exclusive right to acquire up to an 80% interest in Sarape by spending up to US$16.
CDE FR EVM CDEUW AG

42
Mid-Cap Gold Sector  - A Decent Proposal For Growth-Oriented Precious Metals Investors

2018-06-13 seekingalpha
In my opinion, the mid-cap gold sector is the fastest growing segment of the precious metals industry.
CDE NGD EDVVF EDVMF NGDAF CDEUW EVR NGD IAG EDV

30
Kerr Mines Strengthens Executive Team with Appointment of VP Projects and Mine General Manager

2018-05-30 globenewswire
TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX:KER) (OTC:KERMF) (FRA:7AZ1) (“Kerr” or the “Company”) is pleased to announce the appointment of Mr. David Thomas as Vice President of Projects and Copperstone Mine General Manager. This key addition to the Kerr Mines executive management team is central to the Company’s core strategy of moving into production in 2019.
CDE KERMF AISCF KGC K CDEUW TCKRF KER TECK

40
These Mining Stocks Are Following Gold Closely

2018-05-21 marketrealist
In this part of the series, we’ll analyze the correlation of the mining stocks to gold. Gold is the most dominant of the four precious metals, and silver, platinum, and palladium are known to closely track the movement in gold. Also, precious metals, though they belong to the equity segment of the market, are more dependent on where precious metals move, especially gold.
CDE ABX CDEUW ABX

18
Silver: The Second-Favorite Metal

2018-05-18 marketrealist
With continuing downward sentiment in precious metals, it’s important to look at what large traders and hedge funds are doing with their positions in metals. This article focuses on silver, which is predominantly a precious metal and acts as a buffer along with gold during market unrest. Silver was trading at $16.4 per ounce as of 9:00 AM. The resistance level for silver is at a 50-day moving average of $16.
CDE FR PAAS HL CDEUW AG HL.PRB

24
The Slump in Precious Metals and Their Technicals

2018-05-16 marketrealist
All four precious metals witnessed a choppy market on May 15. Gold dropped about 2.1% and closed at $1,288.90 per ounce. This is the lowest level of gold so far this year, and these low levels were last seen in December 2017 for an ~$29.00 decline. The RSI level for gold was 29, which indicates a possible reversion in price.
CDE ELD CDEUW EGO

30
Can Silver Miners Rebound in 2018 after a Long Dry Spell?

2018-05-14 marketrealist
In 2017 and 2018 year-to-date, silver miners considerably underperformed silver. Miners are usually a leveraged play on metals, rising by a higher proportion when metal prices rise and falling harder when metal prices weaken. This trend hasn’t been visible lately as company-specific factors exerted more influence on stock prices.
CDE FR PPPMF PAAS HL CDEUW AG PPP P HL.PRB

54
A Look at the Correlation of Precious Metal Miners

2018-05-09 marketrealist
In this final part of the series, we’ll look at the correlation between gold and four mining stocks: Randgold Resources (GOLD), Yamana Gold (AUY), Coeur Mining (CDE), and Barrick Gold (ABX). Mining stocks generally move with gold prices. Among these four miners, Yamana Gold has shown the highest correlation with gold this year, while Randgold has the lowest correlation on a year-to-date basis.
CDE ABX AUY YRI RGORF CDEUW GOLD RRS GOLD ABX

21
How Precious Metals and Miners Are Reacting in May

2018-05-04 marketrealist
Gold rose 0.62% on Thursday, May 3, after a flat day on Wednesday. Gold futures for May expiration closed at $1,312.10 per ounce. Its RSI level was 30.9, which indicates that there could be a possible rebound in price.
CDE AULGF PAAS AU GDX CDEUW AGG

30
Reading Mining Companies’ Technical Indicators

2018-05-01 marketrealist
During the last month, the market unrest had a significant effect on precious metals, which caused them to rise. However, the previous week was choppy for precious metals, and the US dollar rebounded substantially, which had a negative impact. Most mining companies also faced the adverse effects of the precious metals slump.
CDE AULGF AUY YRI PAAS AU CDEUW SGDM AGG

54
How Upswing in US Dollar Is Affecting Precious Metals

2018-05-01 marketrealist
Out of all the factors that can closely affect gold and other precious metals, the US dollar is the most crucial one. The US dollar, depicted by the US Dollar Index (or DXY), rose 0.45% on Wednesday. It has risen 1.7% in the five days to Wednesday. During the same time, gold fell 2.2%, and silver fell 4.3%. The dollar and precious metals move in opposite directions most of the time. On a YTD (year-to-date) basis, gold has risen 1.
CDE ABX ELD HL CDEUW HL.PRB EGO ABX

262
Top Analyst Upgrades and Downgrades: Amazon, Chipotle, Facebook, General Electric, Intel, Microsoft, Nike, Snap, Symantec and More

2018-04-27 247wallst
Stocks were indicated to have a mixed open on Friday, but the technology-driven Nasdaq was expected to open higher on strong earnings from major tech stocks. Gross domestic product came in above expectations, and the Korean peninsula finally may be working toward an accord. Many investors have considered how they want their investments positioned for the longer term.
SYMC FLEX FB GE HSYFB GEC EAT CARB SCGLY CDEUW CMG CDE NKE AMZN SCGLF TRI GNE MSFT GLE INTC HSY

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...